Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences develops and commercializes medicines for HIV, viral hepatitis, COVID-19 and cancer. Company updates regularly cover product sales and operating results, HIV franchises such as Biktarvy, Yeztugo and lenacapavir, and clinical or regulatory activity for investigational HIV regimens that combine established antiretroviral agents with newer mechanisms.
Recurring developments also include oncology pipeline expansion through Kite cell-therapy programs, the completed acquisition of Arcellx and its investigational BCMA-directed CAR T-cell therapy anitocabtagene autoleucel for multiple myeloma, collaboration activity using real-world evidence in oncology R&D, shareholder matters, and capital-structure disclosures tied to material agreements and acquisitions.
Gilead Sciences (Nasdaq: GILD) has announced a 4.4% increase in its quarterly cash dividend, raising it to $0.71 per share. This adjustment will take effect in the first quarter of 2021, with the dividend payable on March 30, 2021, to stockholders on record as of March 15, 2021. The decision reflects Gilead's ongoing commitment to returning value to shareholders, although future dividends will remain subject to approval by the Board of Directors.
Gilead Sciences (Nasdaq: GILD) announced its Q4 and full-year 2020 results, emphasizing the significant role of Veklury in treating hospitalized COVID-19 patients. CEO Daniel O’Day highlighted the company's commitment to addressing various health needs, including HIV and cancer. Gilead is optimistic about growth opportunities in oncology with Trodelvy, while continuing its leadership in antivirals. Overall, the company is positioned for growth as it enters 2021.
Summary not available.
Gilead Sciences (Nasdaq: GILD) and Gritstone Oncology (Nasdaq: GRTS) have announced a collaboration to develop a vaccine-based immunotherapy aimed at curing human immunodeficiency virus (HIV) infection. The partnership will utilize Gritstone's prime-boost vaccine platform, combining self-amplifying mRNA and adenoviral vectors with antigens from Gilead. Gilead will initially invest $60 million, including a $30 million cash payment and a $30 million equity investment, and has the option for further funding up to $725 million based on clinical milestones.
Gilead Sciences, Inc. (Nasdaq: GILD) is set to announce its fourth quarter and full year 2020 financial results on February 4, following market close. A conference call with management will occur at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the live webcast on the company’s Investors page. Additionally, a replay will be available approximately two hours after the call until February 6. Gilead is dedicated to developing innovative medicines for serious health challenges globally.
Kite, a Gilead Company (Nasdaq: GILD), announced the appointment of Dr. Francesco Marincola as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. Dr. Marincola brings extensive experience in oncology and immunotherapy, previously serving as President and Chief Scientific Officer at Refuge Biotechnologies Inc. His leadership is expected to enhance Kite’s research in CAR T therapies. Kite focuses on innovative cancer immunotherapies, aiming to provide curative cell therapies for patients.
Gilead Sciences (NASDAQ: GILD) and Vir Biotechnology (NASDAQ: VIR) announced a clinical collaboration to explore new therapeutic combinations for chronic hepatitis B virus (HBV). A Phase 2 trial will evaluate therapies involving Gilead's selgantolimod, VIR's VIR-2218, and a PD-1 antagonist. The study aims to achieve a functional cure, defined by the loss of hepatitis B surface antigen (HBsAg) and HBV DNA. Both firms retain rights to their products and will consider future studies based on Phase 2 results. Current therapies require lifelong treatment for over 290 million HBV patients globally.
Gilead Sciences has revised its full-year 2020 guidance, now projecting product sales between $24.30 billion and $24.35 billion, an increase attributed to higher demand for Veklury due to COVID-19. Non-GAAP diluted EPS is forecasted at $6.98 to $7.08, while GAAP diluted EPS is expected to be between ($0.08) and $0.02. R&D expenses are estimated to grow by around 20%, while SG&A expenses are projected to rise by 10%. The company will discuss results in a conference call following its J.P. Morgan Healthcare Conference on January 11, 2021.
Kite, a Gilead Company (Nasdaq: GILD), has partnered with Oxford BioTherapeutics Ltd. to explore five novel oncology targets for hematologic and solid tumors. OBT will validate these targets using its OGAP® discovery platform and create antibodies, with Kite and Gilead securing exclusive rights for development and commercialization. The partnership involves an upfront payment and potential future milestone payments and royalties. Executives from both companies emphasize the collaboration's potential to enhance cancer therapy outcomes.
Gilead Sciences (Nasdaq: GILD) announced that Daniel O’Day, Chairman and CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11 at 12:40 p.m. Pacific Time. The live presentation will be accessible via webcast on Gilead's Investors page, with a replay available for 14 days post-event. Gilead Sciences focuses on discovering and commercializing innovative medicines for unmet medical needs, operating in over 35 countries, with headquarters in Foster City, California.